These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 36928172)
1. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. Sherman G; Lamb GS; Sharma TS; Lloyd EC; Nagel J; Dandam NN; Oliveira CR; Sheikha HS; Anosike BI; Lee P; Vora SB; Patel K; Sue PK; Rubbab B; Yarbrough AM; Ganapathi L; Nakamura MM J Pediatric Infect Dis Soc; 2023 Apr; 12(3):152-155. PubMed ID: 36928172 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343 [TBL] [Abstract][Full Text] [Related]
3. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E; Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429 [TBL] [Abstract][Full Text] [Related]
5. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884 [TBL] [Abstract][Full Text] [Related]
6. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19. Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987 [TBL] [Abstract][Full Text] [Related]
8. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital. Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337 [TBL] [Abstract][Full Text] [Related]
13. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC Trials; 2021 May; 22(1):363. PubMed ID: 34034784 [TBL] [Abstract][Full Text] [Related]
14. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. Bahakel H; Murphy C; Frenck RW; Grimley MS; Marsh RA; Paulsen GC; Haslam DB; Phillips CL; Courter J; Spearman P; Schulert G; Danziger-Isakov L Pediatr Infect Dis J; 2022 Dec; 41(12):985-988. PubMed ID: 36219876 [TBL] [Abstract][Full Text] [Related]
15. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series. Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162 [TBL] [Abstract][Full Text] [Related]
17. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571 [TBL] [Abstract][Full Text] [Related]
18. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients. Yetmar ZA; Bhaimia E; Razonable RR Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253 [TBL] [Abstract][Full Text] [Related]
19. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760 [TBL] [Abstract][Full Text] [Related]
20. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]